NSE filing, NSE: REMUS. Summary written from the filing by ALFA Finder's alert engine.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹843.35
- Market cap
- ₹993.8 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 26.9×Sector 45.9×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals held its 11th Annual General Meeting on September 29, 2026. Shareholders discussed financial results, dividend declaration, and director appointments.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.
Remus Pharmaceuticals Merger & Restructuring
Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.
Other sme to main board migration announcements
All →Basilic Fly Studio SME to Main Board Migration
Basilic Fly Studio's postal ballot approved migration of its equity listing from NSE Emerge to NSE Main Board and BSE Main Board. Voting results and scrutinizer's report were filed with the exchange.
Arham Technologies SME to Main Board Migration
Arham Technologies received NSE approval to migrate from SME Emerge to the Main Board, effective October 30, 2026. Trading under symbol ARHAM starts on the Main Board.
Essen Speciality Films SME to Main Board Migration
Essen Speciality Films received NSE in-principle approval for migrating from the Emerge platform to the NSE Main Board. Completion of migration formalities is still pending.
Karnika Industries SME to Main Board Migration
Karnika Industries seeks shareholder approval via postal ballot to migrate from NSE Emerge to NSE and BSE Main Boards. Voting runs October 29 to November 27, 2026.
Bondada Engineering SME to Main Board Migration
Bondada Engineering received NSE listing approval for migration from BSE SME to NSE Main Board. The milestone broadens investor reach and supports long-term growth.
Felix Industries SME to Main Board Migration
Felix Industries filed an addendum to its scrutinizer's report confirming separate voting for the SME-to-Main Board migration resolution. The Regulation 277 voting threshold was met.